Loading
Led the PORTEC trials that defined who needs radiotherapy for endometrial cancer and brought molecular classification into treatment decisions.
Carien Creutzberg led PORTEC-1, -2 and -3, the Dutch trials that established vaginal brachytherapy over external beam radiotherapy for intermediate-risk endometrial cancer and tested chemoradiotherapy for high-risk disease, and pioneered the integration of the TCGA molecular classification (POLE, MMRd, p53abn, NSMP) into the PORTEC-4a trial and ESGO-ESTRO-ESP guidelines. She co-leads the RAINBO platform of molecularly directed adjuvant trials.
Shares Endometrial cancer and the tags endometrial, radiotherapy.
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.
Shares Endometrial cancer and the tag endometrial.
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.